Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis
Journal of Alzheimer’s Disease · 21.11.2026
DOI: 10.1177/13872877261504983 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 21.11.2026. Verfasst von Arkansh Sharma und 13 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Sleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear.
Objective
To compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs).
Methods
Following PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges’ g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis.
Results
Twelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD −1.09) and WASO (SMD −0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD −0.98), with favorable short-term tolerability. Walking (SMD −0.48), bright light therapy (SMD −0.37), and NITE-AD (SMD −0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD −0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects.
Conclusions
Non-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.
Zitieren
APA
Sharma, A., Raj, R., Azmi, M. O., Puchakayala, N., Kaur, A., S, P., Suresh, V., Datta, A., Deka, A. R., Panchawagh, S., Nithyanandam, A., Malhotra, H. S., Garg, R. K., & Uwishema, O. (2026). Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877261504983
Vancouver
Sharma A, Raj R, Azmi MO, Puchakayala N, Kaur A, S P, et al. Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis. Journal of Alzheimer’s Disease. 2026. doi:10.1177/13872877261504983
BibTeX
@article{Sharma2026,
author = {Sharma, Arkansh and Raj, Rishu and Azmi, Mohammad Orooj and Puchakayala, Nishmitha and Kaur, Anmol and S, Poorvikha and Suresh, Vinay and Datta, Abhigyan and Deka, Anusha Rai and Panchawagh, Suhrud and Nithyanandam, Allimuthu and Malhotra, Hardeep Singh and Garg, Ravindra Kumar and Uwishema, Olivier},
title = {Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis},
journal = {Journal of Alzheimer’s Disease},
year = {2026},
doi = {10.1177/13872877261504983}
}
EUVIMED